[HEPNEWS] valopicitabine plus pegylated interferon

[Guest guest]

Hepatitis C Treatment Effective - 99.94 percent in clinical trialsIdenix: Hepatitis C Treatment Effective 01.10.2005, 03:08 PM Biopharmaceutical company Idenix Pharmaceuticals Inc. reported Monday that its hepatitis C treatment, valopicitabine plus pegylated interferon, reduced levels of the virus by 99.94 percent in clinical trials. Shares of Idenix rose $1.34, or 8.6 percent, to $17 in recent afternoon trading on the Nasdaq. The data was based on a mid-stage trial where 19 patients were treated for 12 weeks. The company said it intends to enroll a trial with 30 patients to assess the safety, antiviral activity and pharmacokinetics of valopicitabine versus valopicitabine plus pegylated interferon. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

volociximab

anti-angiogenic agent to treat solid tumors and age-related macular macular degeneration

http://www.ama-assn.org/ama/pub/category/12363.html